Compounded Tirzepatide vs Zepbound: Safety, Cost and Insurance (2026)

Zepbound and compounded tirzepatide contain the same active ingredient, but they are not the same product. Zepbound is made by Eli Lilly and approved by the FDA. Compounded tirzepatide is prepared by a pharmacy and is not FDA-approved. This guide compares safety, regulation, cost and insurance so you can ask the right questions. Prices were checked in early October 2026.

What is the difference between Zepbound and compounded tirzepatide?

Zepbound is FDA-approved for chronic weight management and, since December 2024, for moderate to severe obstructive sleep apnea in adults with obesity. The FDA has reviewed its safety, effectiveness and manufacturing quality. Compounded tirzepatide is mixed by a compounding pharmacy for individual patients. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.

Is compounded tirzepatide safe?

Compounded tirzepatide is not FDA-approved, so its quality depends on the pharmacy that makes it. The FDA has warned about unapproved GLP-1 drugs, including reports of dosing errors with compounded products and products sold without a prescription or labeled “for research use only.” If you choose a compounded program, ask which pharmacy fills your prescription, check that pharmacy’s state license, and make sure a licensed clinician reviews your health history. Our guide to checking a compounded GLP-1 supplier walks through each step.

Is compounded tirzepatide still legal?

Compounding is legal when a licensed pharmacy prepares a medicine for an individual patient with a valid prescription. During the official tirzepatide shortage, pharmacies had more room to make copies of the brand-name drug. The FDA declared the shortage resolved in December 2024, and since then federal rules limit pharmacies from making routine copies of a commercially available drug. Programs that still offer compounded tirzepatide generally rely on individual patient needs, so ask the program how it is supplied.

How much does Zepbound cost compared with compounded tirzepatide?

Through LillyDirect’s Self Pay Journey Program, Zepbound single-dose vials and KwikPens cost $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg when you refill within 45 days. Miss that window and the price rises to $499 for 7.5 mg and $699 for 10 mg to 15 mg. At a retail pharmacy the list price is about $1,086 a month.

Compounded tirzepatide prices vary by program, plan length and dose. For example, Trimi listed compounded tirzepatide at $235 a month month-to-month or $125 a month on a prepaid annual plan when we checked. Compare programs in our GLP-1 program directory and add every fee with our cost calculator.

Does insurance cover compounded tirzepatide?

Rarely. Insurance plans generally cover FDA-approved medicines, not compounded versions. If your plan covers Zepbound, the savings card can bring it down to as little as $25 a month for commercially insured patients, which can be cheaper than any compounded option. Check your formulary first; our insurance coverage guide explains prior authorization and appeals.

Which should you choose?

• Choose Zepbound if your insurance covers it, if you want an FDA-approved product with clinical trial evidence, or if LillyDirect’s price fits your budget.
• Consider a compounded program only after checking the pharmacy’s license, confirming a licensed clinician reviews your history, and reading the refund and cancellation terms.
• In every case, decide with a licensed clinician who knows your medical history.

For results, side effects and the head-to-head trial, see semaglutide vs tirzepatide and Zepbound vs Wegovy.

Sources and further reading

1. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
2. Eli Lilly and Company. Zepbound (tirzepatide) US Prescribing Information. pi.lilly.com
3. Eli Lilly and Company. LillyDirect self-pay options. lillydirect.lilly.com
4. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov
5. US Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. fda.gov

GLP1Hub does not sell medication. This is general information, not medical advice; talk to a licensed clinician before starting or switching any medication.